- Aptorum Group Limited (NASDAQ:APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus.
- Specifically, two additional cohorts (Cohort C & D) of the single ascending dose portion of the Phase 1 trial in healthy subjects have been completed with no serious adverse events observed.
- No subjects were dropped out of the studies, and no serious adverse events were observed.
- Additionally, no clinically relevant changes regarding vital signs, electrocardiogram, clinical laboratory test results and physical examinations were observed compared to baselines.
- The single ascending dose is still ongoing to gain additional insights into the effect of food on bioavailability and pharmacokinetics.
- On this basis, the company plans to proceed to the multiple ascending dose part in 3Q of 2021.
- In May, the company completed two initial cohorts of the single-dose ascending dose portion of the Phase 1 trial.
- Price Action: APM shares are up 4.64% at $3.16 during the premarket session on the last check Monday.
BTIG Maintains Buy on The Chefs’ Warehouse, Raises Price Target to $48
BTIG analyst Peter Saleh maintains The Chefs' Warehouse (NASDAQ:CHEF) with a Buy and raises the price target from $46 to $48.
